The results demonstrated its ability to reduce blood glucose levels by 5% by increasing glucagon-like peptide 1 (GLP-1) by 17% and decreasing systemic inflammation.
The double-blind, randomised, placebo-controlled crossover study evaluated the standardised extract in reducing blood glucose-related biomarkers.
Study participants were randomly divided into two groups. Each group received a daily dose of the supplement followed by a 2-week washout period. The 26-week study observed the subject's fasting blood glucose levels reduced by 5% at the end of treatment with 200 mg of Eriomin.
“We are thrilled to see that Eriomin continues to show its benefits towards managing prediabetes, a prominent health concern for today’s consumer,” said Rob Brewster, President of Ingredients by Nature.
“One in three Americans have prediabetes, and 400 million people worldwide are already prediabetic. This study further reveals Eriomin’s ability to be a proactive and multifunctional approach to prediabetes management.”
The dosage of 200 mg was chosen after Ingredients by Nature’s previously published study, Effectiveness of Eriomin® in managing hyperglycaemia and reversal of prediabetes condition: a double-blind, randomised controlled study, which showed the lower dose of 200 mg had an effect comparable with the higher amounts of 400 and 800 mg.
However, in the present study, participants were borderline diabetic, with six already hyperglycemic (undiagnosed), whereas the previous study’s participants had hyperglycaemia boarding on prediabetes.
Brewster added: “We plan to conduct additional studies with Eriomin to see how it can further benefit those who need alternatives to pharmaceuticals when controlling their blood sugar levels.”